NHS to offer Wegovy to a million more people in England
The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
Newsletters and Deep Dive digital magazine
The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.
At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
BD-I is a brain-based condition that affects mood and energy regulation to an extent that disrupts daily life.
The EU has approved UCB's Kygevvi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.
Editor's Picks
Newsletters and Deep Dive
digital magazine